Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04464798
Title A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Celgene

follicular lymphoma

Hodgkin's lymphoma

B-cell lymphoma

peripheral T-cell lymphoma


marginal zone B-cell lymphoma



Iberdomide + Obinutuzumab

Iberdomide + Rituximab

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | DEU

No variant requirements are available.